Complete financial analysis of Twist Bioscience Corporation (TWST) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Twist Bioscience Corporation, a leading company in the Medical – Diagnostics & Research industry within the Healthcare sector.
You may be interested
- Shi Shi Services Limited (8181.HK) Income Statement Analysis – Financial Results
- Legible Inc. (LEBGF) Income Statement Analysis – Financial Results
- King Core Electronics Inc. (6155.TW) Income Statement Analysis – Financial Results
- DeepSpatial Inc. (DSAI.CN) Income Statement Analysis – Financial Results
- Facephi Biometria, S.A. (ALPHI.PA) Income Statement Analysis – Financial Results
Twist Bioscience Corporation (TWST)
Industry: Medical - Diagnostics & Research
Sector: Healthcare
Website: https://www.twistbioscience.com
About Twist Bioscience Corporation
Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products. The company's DNA synthesis platform enables the manufacturing of synthetic DNA by writing DNA on a silicon chip. It offers synthetic DNA-based products, including synthetic genes, tools for sample preparation, antibody libraries for drug discovery and development, and DNA as a digital data storage medium. The company has collaboration agreements with Victorian Clinical Genetic Services; Vivlion GmbH.; Kyowa Kirin Pharmaceutical Research, Inc.; deepCDR Biologics AG; and Centogene N.V to develop advanced sequencing tools. It also has a research collaboration with Boehringer Ingelheim International GmbH to use proprietary antibody libraries to discover therapeutic antibodies against multiple targets. Twist Bioscience Corporation was incorporated in 2013 and is headquartered in South San Francisco, California.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 312.97M | 245.11M | 203.57M | 132.33M | 90.10M | 54.39M | 25.43M | 10.77M | 2.27M |
| Cost of Revenue | 179.63M | 155.38M | 119.33M | 80.62M | 61.41M | 47.43M | 32.19M | 24.02M | 9.42M |
| Gross Profit | 133.35M | 89.73M | 84.24M | 51.71M | 28.69M | 6.96M | -6.76M | -13.25M | -7.15M |
| Gross Profit Ratio | 42.61% | 36.61% | 41.38% | 39.08% | 31.85% | 12.80% | -26.59% | -123.09% | -315.20% |
| Research & Development | 90.85M | 106.89M | 120.31M | 69.07M | 43.01M | 35.68M | 20.35M | 19.17M | 18.23M |
| General & Administrative | 0.00 | 186.84M | 210.55M | 133.40M | 102.07M | 78.83M | 42.55M | 25.96M | 18.07M |
| Selling & Marketing | 0.00 | 2.90M | 2.40M | 2.50M | 1.20M | 1.30M | 900.00K | 100.00K | 200.00K |
| SG&A | 218.40M | 189.74M | 212.95M | 135.90M | 103.27M | 80.13M | 43.45M | 26.06M | 18.27M |
| Other Expenses | 44.93M | 10.26M | -1.09M | -1.37M | -182.00K | -265.00K | -121.00K | -55.00K | 73.00K |
| Operating Expenses | 354.18M | 306.89M | 333.26M | 204.97M | 146.27M | 115.81M | 63.80M | 45.23M | 36.50M |
| Cost & Expenses | 533.81M | 462.27M | 452.59M | 285.59M | 207.68M | 163.24M | 95.99M | 69.25M | 45.93M |
| Interest Income | 15.34M | 14.37M | 3.06M | 435.00K | 1.50M | 3.03M | 999.00K | 412.00K | 241.00K |
| Interest Expense | 29.00K | 5.00K | 80.00K | 367.00K | 787.00K | 1.29M | 1.31M | 905.00K | 746.00K |
| Depreciation & Amortization | 31.43M | 29.31M | 36.64M | 11.99M | 6.68M | 6.31M | 5.73M | 5.02M | 4.23M |
| EBITDA | -176.71M | -174.15M | -191.55M | -143.91M | -132.09M | -99.77M | -63.95M | -53.10M | -39.11M |
| EBITDA Ratio | -56.46% | -71.05% | -121.36% | -116.52% | -129.04% | -195.06% | -251.52% | -493.21% | -1,723.80% |
| Operating Income | -220.83M | -217.16M | -249.02M | -153.26M | -117.58M | -108.85M | -70.56M | -58.48M | -43.66M |
| Operating Income Ratio | -70.56% | -88.60% | -122.33% | -115.81% | -130.50% | -200.15% | -277.50% | -543.16% | -1,924.02% |
| Total Other Income/Expenses | 12.67M | 13.69M | 6.50M | -1.30M | 530.00K | 1.47M | -435.00K | -548.00K | -432.00K |
| Income Before Tax | -208.17M | -203.47M | -228.27M | -154.03M | -139.55M | -107.38M | -70.99M | -59.03M | -44.09M |
| Income Before Tax Ratio | -66.51% | -83.01% | -112.14% | -116.39% | -154.88% | -197.44% | -279.21% | -548.25% | -1,943.06% |
| Income Tax Expense | 560.00K | 1.15M | -10.41M | -1.93M | 382.00K | 292.00K | 242.00K | 280.00K | 819.00K |
| Net Income | -208.73M | -204.62M | -217.86M | -152.10M | -139.93M | -107.67M | -71.24M | -59.31M | -44.09M |
| Net Income Ratio | -66.69% | -83.48% | -107.02% | -114.94% | -155.31% | -197.98% | -280.16% | -550.85% | -1,943.06% |
| EPS | -3.60 | -3.60 | -4.04 | -3.15 | -3.57 | -3.92 | -2.68 | -3.16 | -2.35 |
| EPS Diluted | -3.60 | -3.60 | -4.04 | -3.15 | -3.57 | -3.92 | -2.68 | -3.16 | -2.35 |
| Weighted Avg Shares Out | 58.02M | 56.89M | 53.89M | 48.25M | 39.19M | 27.46M | 26.61M | 18.78M | 18.78M |
| Weighted Avg Shares Out (Dil) | 58.02M | 56.89M | 53.89M | 48.25M | 39.19M | 27.46M | 26.61M | 18.78M | 18.78M |
Twist Bioscience Enters into Agreement with Ono Pharmaceutical to Discover Novel Antibodies for Autoimmune Diseases
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced a drug discovery agreement with Ono Pharmaceutical Co., Ltd. (Osaka, Japan; President...
Twist Bioscience: Progress Hidden By Execution Issues And Soft Demand
Twist continues to expand its SynBio and NGS businesses, but its Biopharma business has had execution issues. Twist is focused on reducing costs, but it is still probably at least several years from GAAP profitability. As part of its cost...
Twist Bioscience Releases 2023 ESG Report and Quantifies Carbon Footprint of Manufacturing a Single Gene
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today released its environmental, social and governance (ESG) report for 2023, highlighting Twist's approach...
Biotech Bonanza: 3 Top DNA Stocks With Revolutionary Potential
DNA is as fundamental to biotechnology as it is to biology itself. From synthetic biology to pharmaceuticals, making and using DNA is usually a necessary first step in bringing a biotech product to market.
Twist Bioscience to Present at the UBS MedTech, Tools and Genomics Summit 2023
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that Patrick Finn, Ph.D., president and COO of Twist Bioscience, will participate...
Twist Bioscience Corporation (TWST) Q3 2023 Earnings Call Transcript
Twist Bioscience Corporation (NASDAQ:TWST ) Q3 2023 Results Conference Call August 4, 2023 8:00 AM ET Company Participants Angela Bitting - SVP, Corporate Affairs and EGS Officer Dr. Emily Leproust - CEO and Co-Founder Jim Thorburn - CFO Conference Call...
Why Shares of Twist Bioscience Are Up Friday
Twist makes synthetic biology and next-generation sequencing tools. The company reported improved revenue and reduced losses in the quarter.
Twist Bioscience (TWST) Reports Q3 Loss, Tops Revenue Estimates
Twist Bioscience (TWST) came out with a quarterly loss of $1.01 per share versus the Zacks Consensus Estimate of a loss of $1.14. This compares to loss of $1.08 per share a year ago.
Twist Bioscience Reports Fiscal Third Quarter 2023 Financial Results
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today reported financial results and business highlights for the third quarter of fiscal 2023...
Twist Bioscience to Report Fiscal 2023 Third Quarter Financial Results on Friday, August 4, 2023
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that it will issue its financial results for the fiscal 2023 third...
Source: https://incomestatements.info
Category: Stock Reports